Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
Family confirms death of Israeli-American hostage Hersh Goldberg-Polin
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Ltd ADR
(OP:
ESALY
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eisai Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
March 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In...
Via
Benzinga
The Ruble Is Rubble
March 03, 2022
MSCI says Russian companies are
Via
Talk Markets
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
February 25, 2022
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc's (NYSE: MRK) Keytruda/Lenvima combo therapy for radically...
Via
Benzinga
Dampening Exuberance
February 09, 2022
The bond sell-off halted today but the Fed's plans mean this will resume.
Via
Talk Markets
Weakened Tech Stocks
February 03, 2022
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks.
Via
Talk Markets
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
January 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...
Via
Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
January 12, 2022
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild...
Via
Benzinga
Christmas is Coming
December 23, 2021
November saw a very modest increase in consumer spending, 0.6%. That means we are probably making up for it this month.
Via
Talk Markets
A Bit Of Good News
December 22, 2021
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%.
Via
Talk Markets
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
December 16, 2021
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s...
Via
Benzinga
Uncertain Times
December 15, 2021
The UK inflation rate last month was 5.1%, not a good omen.
Via
Talk Markets
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
November 29, 2021
The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for...
Via
Benzinga
Why Are Biogen Shares Gaining Today?
November 12, 2021
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:...
Via
Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across...
Via
Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...
Via
Benzinga
Chinese Growth Level
October 18, 2021
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.
Via
Talk Markets
Europe's Unicorns
October 15, 2021
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.
Via
Talk Markets
Multiple Bits Of Bad News
September 28, 2021
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser.
Via
Talk Markets
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
September 28, 2021
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab...
Via
Benzinga
A Day Of Huge Market Moves
September 21, 2021
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority.
Via
Talk Markets
Pressure Day
September 13, 2021
Today a recovery came to markets with a particular impact on uranium shares.
Via
Talk Markets
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
A Weak Week
September 10, 2021
Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.
Via
Talk Markets
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
September 10, 2021
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
Via
Benzinga
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma
September 07, 2021
Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-...
Via
Benzinga
Mu - The Newest Worry
September 03, 2021
Today London and New York fell on the huge drop in new employment levels in August.
Via
Talk Markets
Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free
August 30, 2021
Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, ...
Via
Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week
August 29, 2021
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and...
Via
Talk Markets
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
August 31, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
August 29, 2021
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.